RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
RenovoRx announced publication of PK/PD data from its Phase III TIGeR-PaC clinical trial showing that its TAMP platform achieved approximately 51% tumor-site drug extraction with decreased systemic exposure when delivering intra-arterial gemcitabine. The study demonstrated a statistically significant correlation between drug metabolite levels and tumor marker reduction, supporting the platform's targeted delivery mechanism. The company achieved full enrollment in the trial with completion expected in H1 2027 and topline data in H2 2027.